

FORM PTO 1449 (modified)

ATTY DOCKET NO. 076333/0149

09/050,991

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

APPLICANT: Robert H. Getzenberg

FILING DATE: March 31, 1998

GROUP: 1635

LIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO:

MAY 10 2000

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JE	A1	4,882,268	Penman, et al.	435	5	
JE	A2	5,273,877	Fey et al.	435	6	
JE	A3	5,849,509	Coffey et al.	435	7.23	
JE	A4	5,866,535	Getzenberg et al.	514	2	
JE	A5	4,885,236	Penman et al.	435	6	
JE	A6	5,824,490	Coffey et al.	435	7.23	
JE	A7	5,547,928	Wu et al.	514	2	

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
JE	A8	WO95/16919	WIPO			
JE	A9	WO93/09437	WIPO			
JE	A10	WO94/00573	WIPO			
JE	A11	WO87/03910	WIPO			
JE	A12	WO94/18222	WIPO			
JE	A13	WO97/16206	WIPO			

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

JE	A14	Miyana, N., et al., "Nuclear Matrix Proteins as a Urine Marker for Transitional Cell Carcinoma of the Bladder". The Journal of Urology Supplement, Vol. 153, No. 4 (XP-002068914)	4-23-1995, p. 457A
JE	A15	Merrifield, S., et al., "The Performance of the NMP22™ Test Kit: A Quantitative Enzyme Immuno-Assay for Bladder Cancer", <i>Tumor Biology</i> , 17 (suppl 1) (1996). (XP-002068915)	Page 19.
JE	A16	Getzenberg, R., et al., "Bladder Cancer-associated Nuclear Matrix Proteins", <i>Cancer Research</i> Vol. 56, No. 7, pp. 1690-1694, (1996). (XP002068894)	
JE	A17	Konety, B.R., et al., "Identification of Nuclear Matrix Protein Alterations Associated with Renal Cell Carcinoma", <i>The Journal of Urology</i> , Vol. 159, No. 4, pp. 1359-1363 (1998). (XP002068895)	
JE	A18	Eberharter A., et al., "Nuclear Matrix of the lower eukaryote <i>Physarum polycephalum</i> and the mammalian epithelial LLC-PK <sub>1</sub> cell line -- A comprehensive investigation of different preparation procedures", Vol. 212, No. 2 pp. 573-580 (1992). (XP02068893)	
JE	A19	Keese, S.K., et al., "Utilization of Nuclear Matrix Proteins for Cancer Diagnosis", <i>Critical Reviews in Eukaryotic Gene Expression</i> , Vol. 6, No. 2&3, pp. 189-214 (1996). (XP002069158)	
JE	A20	Getzenberg, R. H., "Nuclear Matrix and the Regulation of Gene Expression: Tissue Specificity", <i>Journal of Cellular Biochemistry</i> , Vol. 55, pp. 22-31 (1994).	
JE	A21	Getzenberg, R.H., et al., "Identification of Nuclear Matrix Proteins in the Cancer and Normal Rat Prostate", <i>Cancer Research</i> , Vol. 51, pp. 6514-6520 (1991).	
JE	A22	Berezney, R., et al., "Identification of a Nuclear Protein Matrix", <i>Biochemical and Biophysical Research Communications</i> , Vol. 60, No. 4 (1974).	p. 1410-1417.
JE	A23	Fey, E.G., et al., "The Nuclear Matrix: Defining Structural and Functional Roles", <i>Eukaryotic Gene Expression</i> , pp. 127-143 (1991).	

A24	Fey, E.G., <i>et al.</i> , "Tumor promoters induce a specific morphological signature in the nuclear matrix-intermediate filament scaffold of Madin-Darby canine kidney (MDCK) cell colonies", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 81, pp. 4409-4413 (1984).
A25	Fey, E.G., <i>et al.</i> , "Nuclear matrix proteins reflect cell type of origin in cultured human cells", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 85, pp. 121-125 (1988).
A26	Fey, E.G., <i>et al.</i> , "Epithelial Cytoskeletal Framework and Nuclear Matrix-Intermediate Filament Scaffold: Three-dimensional Organization and Protein Composition", <i>The Journal of Cell Biology</i> , Vol. 98, pp. 1973-1984 (1984).
A27	Weidner, N., <i>et al.</i> , "Rapid Communication, Localization of Nuclear Matrix Proteins (NMPs) in Multiple Tissue Types with NM-200.4™ (An Antibody Strongly Reactive with NMPs Found in Breast Carcinoma)", <i>American Journal of Pathology</i> , Vol. 138, No. 6, pp. 1293-1298 (1991).
A28	Huse, W.D., <i>et al.</i> , "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda", <i>Research Article</i> , pp. 1275-1281 (1989).
A29	Mullinax, R.L., <i>et al.</i> , "Identification of human antibody fragment clones specific for tetanus toxoid in a bacteriophage $\lambda$ immunoexpression library", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 87, pp. 8095-8099 (1990).
A30	Diener, E., <i>et al.</i> , "Specific Immunosuppression by Immunitoxins Containing Daunomycin", <i>Science</i> , Vol. 231, pp. 148-150 (1986).
A31	Greiner, J.W., "Recombinant Interferon Enhances Monoclonal Antibody—Targeting of Carcinoma Lesions in Vivo", <i>Reports</i> , pp. 895-898 (1987). <i>SCIENCE Vol. 235, Iss. 4791</i>
A32	Wolff, B., <i>et al.</i> , "The Use of Monoclonal Anti-Thy <sub>1</sub> IgG <sub>1</sub> for the Targeting of Liposomes to AKR-A Cells In Vitro and In Vivo", <i>Biochimica et Biophysica Acta</i> , Vol. 802, pp. 259-273 (1984).
A33	Weintraub, H.M., "Antisense RNA and DNA", <i>Scientific American</i> , pp. 40-46 (1990). <i>January</i>
A34	Cech, T.R., PhD., "Ribozymes and Their Medical Implications", <i>JAMA</i> , Vol. 260, No. 20, pp. 3030-3034 (1988).
A35	Haseloff, J., <i>et al.</i> , "Simple RNA enzymes with new and highly specific endoribonuclease activities", <i>Nature</i> , Vol. 334, pp. 585-591 (1988).
A36	Bejany, D.E., <i>et al.</i> , "Malignant Vesical Tumors Following Spinal Cord Injury", <i>The Journal of Urology</i> , Vol. 138, pp. 1390-1392 (1987).
A37	Kaufman, J.M., <i>et al.</i> , "Bladder Cancer and Squamous Metaplasia in Spinal Cord Injury Patients", pp. 967-971 (1977). <i>Journal of Urology Vol. 118, No. 6</i>
A38	Melzak J., M.D., "The Incidence of Bladder Cancer in Paraplegia", <i>Paraplegia</i> , pp. 85-96 (8/1996) <i>Vol. 4</i>
A39	Nyquist, R.H., M.D., <i>et al.</i> , "Mortality and Survival in Traumatic Myelof During Nineteen Years, from 1946 to 1965", <i>Paraplegia</i> , pp. 22-48. (May 1967) <i>Vol. 5 (1)</i>
A40	El-Masri, W.S., "Bladder Cancer After Spinal Cord Injury", <i>International Medical Society of Paraplegia</i> , pp. 265-270 (1981). <i>Vol. 19, No. 5</i>
A41	Geisler, W.O., <i>et al.</i> , "Survival In Traumatic Transverse Myelitis", <i>Paraplegia</i> , Vol. 14, pp. 262-275 (1977).
A42	Hackler, R.H., "A 25-Year Prospective Mortality Study In The Spinal Cord Injured Patient: Comparison With The Long-Term Living Paraplegic", <i>The Journal of Urology</i> , Vol. 117, pp. 486-488 (1977).
A43	Pound, C.R., <i>et al.</i> , "Differential Nuclear Matrix Protein (NMP) Patterns In Normal Renal Tissue And Renal Cell Carcinoma (RCC)". 92 <sup>nd</sup> Annual Meeting of the American Urological Association, New Orleans, LA, USA (1997) <i>J. of Urol.</i> , Vol. 157 (4 suppl.) (1997) (XP-002076374) <i>p. 279</i>
A44	Konety, B.R., <i>et al.</i> , "Characteristic Nuclear Matrix Protein Alterations In Renal Cell Carcinoma (RCC)". 92 <sup>nd</sup> Annual Meeting of the American Urological Association, New Orleans, LA, USA (1997) <i>J. of Urol.</i> , Vol. 157 (4 suppl.) (1997) (XP-002076375) <i>p. 276</i>
A45	Gordon, J.N., <i>et al.</i> , "Altered Extracellular Matrices Influence Cellular Processes and Nuclear Matrix Organizations of Overlying Human Bladder Urothelial Cells", <i>Cancer Research</i> , Vol. 53, pp. 4971-4977 (1993).
A46	Cupo, J., "Electrophoretic analysis of nuclear matrix proteins and the potential clinical applications", <i>Elsevier Science Publishers B.V.</i> , pp. 389-406 (1991).
A47	Partin, A.W., <i>et al.</i> , "Nuclear Matrix Protein Patterns in Human Benign Prostatic Hyperplasia and Prostate Cancer", <i>Cancer Research</i> , Vol. 53, pp. 744-746 (1993).
A48	Russell, P.J. <i>et al.</i> , "Preclinical studies of monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer," <i>Cell biophysics</i> , Vols. 24/25, pp. 155-61 (1994)

A49	Kingsley E.A. et al., "Characterisation of the anti-bladder-cancer monoclonal antibody BLCA -8: identification of its antigen as a neutral glycolipid," Cancer Immunology, Immunotherapy, Vol. 41, No. 6, pp. 348-54 1995) (XP000872998)
A50	Fradet Y., "Molecular and immunologic approaches in the management of bladder cancer," Urologic Clinics of North America, Vol. 18, No. 3, pp. 515-24 (1991) (XP000881253)
A51	Replogle-Schwab R. et al., "The utilization of nuclear matrix proteins for cancer diagnosis," Critical Reviews in Eukaryotic Gene Expression, Vol. 6, Nos. 2-3, pp. 103-13 (1996) (XP000881255)
A52	Pirtskalaishvili G. et al., "Use of urine-based markers for detection and monitoring of bladder cancer," Techniques in Urology, Vol. 5, No. 4, pp. 179-84 (1999) (XP000881344)
A53	J.E. Celis et al., "Expression of the transformation-sensitive protein "cyclin" in normal human epidermal basal cells and simian virus 40-transformed keratinocytes," Proc. Natl Acad. Sci. USA, Vol. 81, pp. 3128-3132 (1984)
A54	J.E. Celis et al., "Intermediate filaments in monkey kidney TC7 cells: Focal centers and interrelationship with other cytoskeletal systems," Proc. Natl Acad. Sci. USA, Vol. 81, pp. 1117-1121 (1984)
A55	R. G. DiScipio et al., "Nucleotide sequence of cDNA and derived amino acid sequence of human complement component C9," Proc. Natl Acad. Sci. USA, Vol. 81, pp. 7298-7302 (1984)
A56	R.B. Merrifield, "Solid Phase Peptide Synthesis. I. The synthesis of a Tetrapeptide," J. Am. Chem. Soc., Vol. 85, No. 14, pp. 2149-2154 (1963)
A57	Stewart and Young, "Solid Phase Peptide Synthesis," Freeman Publ. 1969, pp. 27-61
A58	J.Y. Douillard et al., "Monoclonal Antibodies Specific Immunotherapy of Gastrointestinal Tumors," Hybridoma, Vol. 5, Suppl. 1 (1986) pp. S139-S149
A59	Matritech, NMP22® Test Kit (6/96) pp. 1-39
A60	R. Fraley et al., "New Generation liposomes: the engineering of an efficient vehicle for intracellular delivery of nucleic acids," Trends Biochem. Sci., Vol. 6, pp. 77-80 (1981)
Janet E. [Signature]	
DATE CONSIDERED 12-15-00	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.